Clinical Trial Update: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial [Phase 2]

View source ↗

Summary

Phase 2 PAPMET2 trial evaluates cabozantinib with or without atezolizumab in patients with advanced papillary renal cell carcinoma, including metastatic or Stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• cabozantinib (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING